ERBB2 and colorectal carcinoma: Moreover, a phase I/Ib study (DASH; NCT04704661) is currently testing the safety and tolerability of a combinatorial treatment of T-DXd and AZD6738 (ceralasertib), an Ataxia telangiectasia and Rad3 related (ATR) kinase inhibitor, in CRC patients with a change in the HER2 gene or protein.